Engineering of Surface Proteins in Extracellular Vesicles for Tissue-Specific Targeting by Vogt, Stefan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Engineering of Surface Proteins  
in Extracellular Vesicles for  
Tissue-Specific Targeting
Stefan Vogt, Gerhard Stadlmayr, Johannes Grillari, 
Florian Rüker and Gordana Wozniak-Knopp
Abstract
Extracellular vesicles (EVs) have in the recent decades gained an important 
stand as vehicles enabling cell-to-cell transport and communication. With the 
advanced development towards their clinical use and increasing versatility of 
potential applications, improving their tissue-specific targeting in order to enhance 
their functionality in drug delivery opened as a challenging engineering field. In the 
past, the question of specific intercellular contact has been addressed by decora-
tion of the EV surface with agents able of specific target recognition. An attractive 
possibility here is the modification of strongly overexpressed EV surface marker 
proteins towards recognition of target cells. As these proteins are involved in a 
plethora of biological functions in EV biogenesis, cargo targeting and intercellular 
transfer, a minimal impact on protein architecture upon modifications is desirable, 
which would also increase the stability of the exosomal preparation intended for 
therapeutic use. This chapter focuses on the possibilities of engineering of the EV 
marker proteins towards antigen-recognition units broadly applicable to endow EVs 
with tissue-targeting functionality.
Keywords: extracellular vesicles, exosomes, tetraspanin, tissue-specific targeting, 
exosomal drug delivery
1. Introduction
The transfer of extracellular vesicles (EVs) has emerged in the last two decades 
as a novel mechanism for intercellular communication. Nomenclature of EVs has by 
now been agreed to be based on biogenesis pathway. Therefore, EVs budding from 
plasma membranes are termed ectosomes or microvesicles, while exosomes are 
formed via the endosomal compartment within multivesicular bodies (MVB) which 
then are released by their fusion with the plasma membrane. Finally, when blebbing 
from apoptotic cells, the term apoptotic bodies has been retained [1]. Biomarkers to 
differentiate these EVs are still questionable, and in general, size is used to differ-
entiate exosomes from ectosomes, while apoptotic bodies are considered to present 
phosphatidylserine on the outside and thus can be stained by annexin V. Exosomes 
(40–150 nm in diameter) are produced by formation of endosomal intraluminal 
vesicles (ILVs) in multivesicular bodies (MVBs) and are secreted by fusion of these 
vesicles with the plasma membrane [2, 3] (Figure 1).
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Since they have been known to mediate directional intercellular transfer of their 
content, typically proteins, mRNAs, microRNAs (miRNAs) and a variety of non-
coding RNAs [4], several studies were oriented towards their application as drugs  
per se or as therapeutic tool for drug delivery [5]. Their membrane is strongly 
enriched in sphingomyelin and cholesterol, which contributes to their unique buoy-
ancy coefficient and enables practical isolation from other particles of cellular origin 
using differential centrifugation methods. Another discernible feature of exosome 
membranes is that it reflects the composition of the MVB membrane and has a high 
density of endosomal membrane proteins, such as proteins involved in MVB biogen-
esis (Alix and TSG101), membrane transport, in particular the components of the 
endosomal sorting complex required for transport (ESCRT) and most prominently 
tetraspanin proteins (CD9, CD37, CD53, CD63, CD81, CD82 and CD151) [6, 7]. Some 
tetraspanins such as CD9, CD81 and CD151 are more broadly expressed, while others 
are restricted to specific EV subsets [8, 9]. The overexpression of tetraspanins, as 
shown for CD9, can in several production cell lines enhance the exosome production 
and, in addition, cause a reduced overall size of the vesicles [10].
Tetraspanins play an important role in several physiological processes [11] and 
have been discovered to cooperate in states of health and disease in signal transduc-
tion, cellular activation, polarization, motility, adhesion, tissue differentiation, 
angiogenesis, tumorigenesis and metastasis [12–14], both by regulating cellular 
interactions as cell-membrane bound molecules and indirectly through exosomes. 
They are involved in each step of the metastatic cascade due to their ability to inter-
act with cell surface receptors, adhesion molecules, matrix-remodeling proteases and 
signaling molecules. In this pathological state, they hence regulate cell proliferation, 
participate in epithelial-mesenchymal transition, modulate integrin-mediated cell 
adhesion and mediate the invasion through modulation of angiogenesis, tumor-
endothelial cell interactions and regulation of cancer cell migration through the 
regulation of tumor microenvironment, as well as direct influence on extracellular 
matrix [15]. In this chapter, we introduce the characteristics of EVs and the engineer-
ing approaches aimed at their surface proteins to achieve tissue-specific targeting.
2. Structure of the tetraspanin proteins
The rod-shaped structure of a tetraspanin consists of four transmembrane 
helices that connect the two extracellular loops [16] (Figure 2). The short extra-
cellular loop (SEL), which has not yet been reported to contain any element of a 
Figure 1. 
Biogenesis of EVs.
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particular secondary structure, is of 12–31 amino acids in length. In the studies 
oriented towards tetraspanin engineering, the EC1 domain has until now been less 
addressed due to its lower degree of structural organization. Its replacement for a 
strand of glycine-serine residues has led to an unusual cell surface expression and 
a distribution dissimilar to the wild-type parental molecule, which may suggest 
the importance of this structural subunit for the stability of the membrane-bound 
tetraspanin [17].
The large extracellular loop (LEL) or extracellular domain 2 (EC2) has on the 
other hand been well characterized. The crystal structure of CD81 [18] demon-
strated the four invariant cysteine resides within EC2 to form the 2 disulfide bridges, 
as a hallmark stability feature of the conserved tetraspanin fold [8, 19] (Figure 2). 
Moreover, the topology of several other tetraspanins was predicted by molecular 
modeling studies in the absence of an available crystal structure, using the CD81 EC2 
structure as a template: these were the tetraspanins CD37, CD53, CD82 and CD151 
[20, 21]. It has been early established that binding of CD81-specific antibodies 
depends on the formation of the disulfide bonds [22]. One class of tetraspanins har-
bors the EC2 composed of five α-helical elements, forming stalk and head elements 
of a mushroom-like structure, and the second class of tetraspanins is postulated 
to contain an additional helical element, stabilized with another pair of cysteine 
residues. The EC2 fold structure is evolutionarily conserved across species for any 
particular tetraspanin in spite of a high degree of variability at the amino acid level 
[23], with a subdomain consisting of a three-helix-bundle fold and a second subdo-
main variable in size among members of the tetraspanin family [18, 20].
The presence of an energetically unfavorable hydrophobic patch and the 
dimeric form of CD81 LEL in a crystal hinted at the high likelihood of tetraspanin 
assembly into dimers or multimers in the cell membrane. As shown later, clustering 
of tetraspanins leads to the organization of tetraspanin-associated proteins in a 
tetraspanin web or tetraspanin-enriched microdomain (TEM) [24, 25]. Biologically, 
such domains induce partitioning of the complexes into lipid rafts and clustering of 
the lipid rafts [26].
Apart from the hydrophobic interactions of the extracellular domains, the mem-
brane-proximal cysteines residing in transmembrane domains contribute to the 
dimer formation and stability of tetraspanins. For the CD9 tetraspanin, it has been 
demonstrated that these residues are positioned close to the dimerization interface 
and influence homotypic and heterotypic tetraspanin association depending on 
their reversible palmitoylation status [27]. Similarly, the mutation of N-terminal 
Figure 2. 
Organization of tetraspanin CD81: 4 transmembrane helices (TM) span 2 extracellular loops. Positions of 
cysteine residues are indicated with yellow dots. Crystal structure of EC2 domain is presented as a cartoon 
diagram of the dimeric form (PDB: 1G8Q ); the conserved three-helix bundle is black and the variable 
domains C and D are surfaced in blue or green for each protomer. The figure was prepared using PyMOL 
(PyMOL molecular graphics system, version 1.3 Schrödinger, LLC).
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and C-terminal transmembrane cysteines to serine eliminated palmitoylation of 
CD151, which turned out to be deleterious for the assembly with other cell surface 
proteins, including tetraspanins CD9 and CD63, their organization to TEMs and 
subsequently their subcellular distribution and cell morphology [28]. At the same 
time, it had minimal influence on the density of tetraspanin protein complexes and 
was dispensable for CD151-α3β1 integrin association. Depalmitoylation of CD81 
did not impact its surface expression and stability, but rendered it less available 
for contact with its natural interaction partner CD9 and the relevant epitopes less 
accessible for binding of structurally dependent antibodies [29].
The four transmembrane helices of tetraspanin proteins form two largely 
separated pairs of antiparallel helices: one pair comprises TM1/TM2 and the other 
TM3/TM4. The two pairs of helices only converge close to the cytoplasmic side 
of the membrane through contacts between TM2 and TM3. In the recently solved 
crystal structure of full-length CD81, this cone-like structure has been shown to 
harbor a binding pocket for cholesterol [30], and mutations within transmembrane 
domains in certain tetraspanins have been connected with pathological states [31]. 
The short cytoplasmic tails show no obvious functional significance in signaling 
processes, suggesting that their signaling competence relies on association with 
other molecules [32]; nevertheless, its mutation can lead to different assembly with 
association partners as shown for CD9 [33].
3. Natural ligands of tetraspanin proteins
3.1 The tetraspanin web and intertetraspanin contacts
The ability of members of the tetraspanin family to assemble into a unique 
biological feature known as tetraspanin-enriched microdomain (TEM) is due 
to their mutual interactions; however, these structures include also receptors, 
integrins and signaling molecules such as phosphatidyl-kinase C (PKC) and 
phosphatidylinositol-4-kinase (PI4K) [9]. These interactions are fundamental for 
cellular functions such as cell adhesion, proliferation and motility. Interactions 
between tetraspanin members are important in maintaining the integrity and 
stability of the tetraspanin web and providing binding sites for different ligands. 
The multimers of newly synthesized proteins are formed in the Golgi apparatus. 
The predominantly cross-linked tetraspanin species are homodimers, but also 
higher order complexes and low amounts of heterodimeric tetraspanins (CD81/
CD9, CD9/CD151, CD81/CD151) were identified [27]. It has been suggested that 
tetraspanin homodimers, formed in the Golgi and present at the cell surface, 
serve as building blocks in the assembly of higher organized tetraspanin protein 
complexes. Interestingly, the exosomes originating from cell lines overexpressing 
CD9 are believed to be enriched in more stable TEMs [10]. Overall, although most 
tetraspanins can interact with most other tetraspanins, and similarly engage with 
several other proteins, the nature of these interactions has been until recently 
classified only according to their stability in the presence of detergents of differ-
ent stringency, which does not necessarily reflect their significance in the cellular 
milieu [34]. A thorough characterization of strength and abundance of the interac-
tions between the members participating in a tetraspanin web in a particular cell 
and physiological situation is therefore needed and will support the understanding 
of its mediated biological effects. Similarly, most data on tetraspanin functionality 
come from studies on their localization on cell membranes, while functional data 
in vesicles are still scarce. Therefore, we here summarize the known cellular func-
tions, while speculating how this might translate to EVs.
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An important step towards the understanding of the specificity of the tetraspanin 
interactions in TEM has been achieved by delineation of the involved tetraspanin 
regions by dissecting the model tetraspanin into domains, differently amenable for 
modification. Early experiments that addressed the relatively unstructured and 
at the same time antigen-binding competent regions that appeared attractive for 
mutagenesis resulted in a protein that showed aberrant clustering involving both 
homo- and heterodimerization of resulting full-length tetraspanins [35], albeit the 
mutagenesis method employed in this study was a complete deletion of targeted 
domains. The CD81 D-region was studied in more detail: the CD9 and CD151 
tetraspanins were more competent of clustering with CD81 when homologously 
engrafted with CD81 D-region [36]. When the mutagenized CD81 EC2 molecular 
subunits were transplanted to other tetraspanins, the extremely flexible conforma-
tion of the solvent-exposed D-segment of CD81 EC2 was sufficient to overcome the 
orientational restrictions to initiate the homotypic contact for dimerization, and this 
finding has been corroborated with both wet-lab data and the insights from molecu-
lar dynamic simulation of the cell membrane-embedded protein [37].
3.2  Interaction of tetraspanins with integrins and matrix-degrading enzymes: 
role of tetraspanins in cancer and metastasis
Important association partners of tetraspanins are the integrins. The role of 
such complexes in invasive growth in vivo as well as the effect of integrin-mediated 
binding events on cell proliferation and invasion is well established. Especially, the 
laminin-binding integrins (α6β4, α3β1, α6β1 and α7β1) exhibit extensive interactions 
with tetraspanin proteins [12, 38]. The functionality of integrins may depend criti-
cally on their interaction of tetraspanins: it has early been described that the remark-
ably stable association of the tetraspanin CD151 and the integrin α3β1 leads to a high 
level of activation of cellular PI4K [39]. Further, CD151 interacts directly with the α3 
subunit and links it to other tetraspanins, CD9 and CD81. Loss of CD151 abrogates 
the α3β1 mediated mobility on its ligands, laminin-332 and laminin-551. CD9/CD81 
complex may even regulate the integrin-mediated functions independently of CD151 
by forming a complex with the integrin and directing the PKCα-α3β1 association [40]. 
Another example of tetraspanin-integrin association reveals its proangiogenic role 
through VEGF induction, mediated by cooperation between TM4SF5 and integrin 
α5 of epithelial cells [41]. Interestingly, removal of CD151 palmitoylation sites did 
not disrupt the CD151–α6β4 complex in epithelial cells but strongly influenced α6β4-
integrin–dependent cell morphology [42]. The rat tetraspanin D6.1A (human homolog 
is CO-029) was able to induce systemic angiogenesis by initiation of an angiogenic loop 
that reached organs distant from the tumor, probably due to the abundance of D6.1A 
in tumor-derived exosomes. This is in line with reports claiming that EVs prepare 
niches for metastatic tumor cells at tissues distant from the primary tumor [43]. This 
tetraspanin associates with integrins α3β1, α6β1 and α6β4, as well as with tetraspanins 
CD9 and CD81, and is similarly to CD151 linked to tumor-promoting activities [44].
Active complexes of tetraspanins and integrins influence biological processes 
other than cellular signaling by interacting with cellular metalloproteinases, impor-
tant players in the remodeling of extracellular matrix. A study of MDA-MB-231 cells, 
a breast cancer cell line, has indicated that the α3β1-tetraspanin protein complex 
may be linked to an invasive phenotype of tumor cells via modulation of vari-
ous signaling pathways, including activation of membrane metalloproteinase-2 
(MMP-2), an enzyme associated with invasive migration of the cells, and affect-
ing phosphatidylinositol-3-kinase (PI3K) signaling pathways, which control actin 
cytoskeleton dynamics [45]. By the incorporation of the members of a disintegrin and 
metalloproteinase (ADAM) family members the tetraspanins are able to influence the 
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cellular ectodomain cleavage and release activity of these enzymes [46]. The tetraspa-
nins of the TspanC8 group (tetraspanins with 8 cysteines) have a significant impact 
on the cellular exit and catalytic activity of ADAM10 [47], in particular the activity 
of Tspan15/ADAM10 promoted N-cadherin cleavage [48–50]. Different TspanC8/
ADAM10 complexes seem to have different substrate specificities [51]. The silencing 
of CD9 enhanced shedding of ADAM17-substrates TNF-α and ICAM-1 [52].
Important discovery of the possible consequences of fine differences in compo-
sition of TEMs has been delivered by the study of exosomes enriched in Tspan8-α4 
complex that were preferentially taken up by the endothelial and pancreatic cells 
[53]. The fact that such modifications can allow selective targeting in vitro and in 
vivo holds promise to achieve improved exosomal delivery by engineering of their 
membrane components.
3.3 The role of tetraspanins in immune complexes
In antigen-presenting cells (APCs), tetraspanins integrate into TEMs protein-
recognition receptors binding to conserved repeated motifs of microbes, such as 
Toll-like receptors, and MHCII molecules into tetraspanin web platforms, as well 
as Fcγ receptor I in phagocytic cells, Fcγ receptor IIb and III upon the activation of 
macrophages and Fcε receptor I in monocytes and skin-derived dendritic cells [54].
The particular role of CD81 protein in the formation of specialized microdomains 
in the plasma membrane of the cells of the immune system was discovered by eluci-
dating its function of recruiting various adhesion molecules, receptors and signaling 
proteins to the central zone of the immune synapse in T-lymphocytes and APCs [55]. 
Therefore, it has early been proposed for CD81 to play a key role during antigenic 
presentation, since it colocalizes with the T-cell receptor/CD3 [56], and CD81 indeed 
turned out to be a regulator of CD3 clustering and sustained CD3 signaling [57].
Further, the T-cell side of the immune synapse is densely populated by tet-
raspanins CD9 and CD151. The abolishment of their expression reduces markers 
of activation of T-lymphocytes conjugated to the APCs, such as IL-2 secretion and 
expression of CD69 [58].
Another role in the immune response of tetraspanin CD81 is amplifying and 
sustaining B-cell receptor signaling from lipid rafts by ligation to the co-receptor 
CD19/CD21 complex. The signaling through a variety of cell surface protein 
complexes implies a role of lipid rafts, again highlighting the ability of tetraspanin 
to facilitate raft association [9].
3.4 Tetraspanins in pathogen infection
Several studies have been oriented towards the research of tetraspanins as ligand 
molecules for pathogen entry. CD81 has been identified as a ligand for hepatitis C 
virus (HCV) recognition and viral entry [59]. The ligand for viral glycoprotein E2 
is the D-domain of the LEL, a dynamic region positioned within the triple-bundle 
helix, whose conformation in solution differs substantially from the one suggested 
by crystal structure. Challenging for structure-based design, this region neverthe-
less presents an attractive target for design of therapeutically relevant ligands with 
methods such as NMR [60]. Apart of the EC2 domain, other regions of CD81 have 
proven important for virus infection. Experimental evidence here was based on the 
exchange of the structural domains of the molecule with the ones of tetraspanins of 
different degrees of homology, and it was found that closely related substitutions 
were more efficient at functional complementation of CD81. Viral entry has been 
shown to correlate with surface expression of the chimeric protein and to depend 
on the presence of the cholesterol-coordinating glutamate residue [61]. EWI-2wint, 
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a cleavage form of EWI-2, a member of the immunoglobulin superfamily, has an 
inhibitory effect on HCV infection by obstructing the interaction between CD81 
and HCV E2 [62]. The related factor EWI-F inhibits Plasmodium infection, whereas 
its silencing increases infection efficiency [63].
Tetraspanin microdomains have been described to regulate HIV-1 entry, assem-
bly and transfer between the cells [64, 65]. CD81 influences importantly the early 
stages of virus replication by controlling the stability of HIV-1 restriction factor and 
consequently the activity of viral reverse transcriptase [66], while CD63 facilitates 
endocytosis of the HIV receptor CXCR4 [67] as well as supports the replication steps in 
macrophages [68, 69]. Also Coronaviruses and low-pathogenicity Influenza A viruses 
utilize TEM domains as entry portals to co-engage with cellular receptors and proteases, 
which enable viral proteolytic priming [70]. As shown in an in vivo model with CD151 
null-mice, this tetraspanin is a critical novel host factor of nuclear export signaling of 
Influenza A virus, used complementary to the viral nuclear export proteins [71].
Tspan9 modulates the early endosome compartment to make it more permis-
sive for membrane fusion of early-penetrating viruses, and its depletion strongly 
inhibits infection by alphaviruses that fuse in early endosomes but does not alter the 
delivery of virus to early endosomes or change their pH or protease activity [72]. 
It is unclear, what function then EV-based tetraspanins might have in the context 
of viral infection, and it might be speculated that cells use EVs to titrate away 
virus into membrane structures that are unable to provide replication and protein 
synthesis machineries for the virus. This is supported by the findings that EVs might 
have anti-influenza infection activity in vitro [73].
4. Extracellular vesicles as mediators of cell-cell interaction
4.1  Biological basis for therapeutic applications: EVs as mediators of intercellular 
interactions
EVs are secreted by most cell types and are taken up by recipient cells, where 
their cargo consisting of a cocktail of proteins, mRNAs and non-coding RNAs alters 
the behavior of the recipient cells in a way that might be even considered similar 
to hormones or cytokines [74], e.g. in the context of skin or bone cell paracrine 
signaling [75–77]. siRNAs (small interfering RNAs) and miRNA-based inhibitors 
have been recognized as potent novel drug candidates for many years. As EVs can 
be loaded with different drugs in vitro, they qualify as an attractive drug delivery 
system. The specificity of the recipient cell targeting in vivo is understood in a lim-
ited way only, although there is evidence of accumulation of specific EVs [43]. For 
example, EVs from human mesenchymal stem cells accumulated in the liver, spleen 
and sites of acute kidney injury [78]. Such tropism for a specific cell type, a require-
ment for targeted drug delivery, appears to be determined by surface proteins of the 
source cells. The composition of EV membrane reflecting the one of their source 
cell makes these particles non-immunogenic, and their small size allows them to 
pass the immune surveillance of the host organism [79, 80]. The reported engage-
ment of exosomes in physiological processes in normal and diseased central nervous 
system makes them attractive vehicles for delivering neurotherapeutic agents across 
the blood-brain barrier [81–83]. Nevertheless, their delivery in humans seems so far 
limited to liver and kidney as they are reported not to reach therapeutic amounts in 
brain, heart and other tissues due to lack of specific targeting and thus low enrich-
ment of the intended therapeutic ingredient in the target tissue. Modifications of 
the EV surface membrane to achieve enhanced targeting of a specific cell type are 
hence a common strategy embodied in several different engineering approaches.
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4.2 Mechanisms of EV entry into the target cell
When an EV attaches to the target cell surface, it can in some cases activate 
the cognate receptors without internalization or transfer of the content to the 
recipient cell via its fusion with the target cell membrane or via endocytosis [84]. 
Endocytosis is an active process that requires cytoskeletal remodeling dependent 
on actin dynamics and includes clathrin-dependent endocytosis, phagocytosis 
and macropinocytosis. The clathrin-dependent endocytosis has been established 
as cellular entry for EVs based on the experiments with specific inhibitors of this 
pathway. Additionally, endocytic uptake of EVs can involve lipid rafts, sometimes 
dependent on caveolin proteins. The size of EVs may be a limiting factor for cellular 
entry via endocytosis [85]. The EV uptake by phagocytosis was monitored by their 
high level of accumulation in phagocytic cells and localization into the phagolyso-
some [86], as well as the identification of the crucial role of the phosphatidylserine 
binding T-cell immunoglobulin and mucin domain containing (TIM4) receptor for 
the uptake of exosomes into macrophages [87, 88]. The contribution of macropino-
cytosis pathway was revealed with studies where exosomal uptake was decreased 
by the inhibition of cytoskeletal rearrangements that normally lead to membrane 
ruffles [89], as well as with its promotion caused by the activation of the agonisti-
cally acting epidermal growth factor [90].
5.  Molecular engineering to facilitate EV labeling and delivery to target 
cells
5.1  Modifications of EV membrane with non-covalent and chemical 
modifications
The role of EVs as encapsulated intercellular messengers makes them attractive 
for development into nanoscale therapeutic agents [91], and therefore, the need of 
augmenting the interaction with the recipient cell has been widely recognized. The 
higher rigidity of the membrane of EVs in comparison with their source cells does 
not appear to obstruct the efficient application of common hydrophobic insertion 
strategies to EVs. The introduction of small lipophilic ligands, such as membrane 
dyes, works effectively for their labeling and aids in monitoring in in vitro and in 
vivo experiments. Furthermore, hydrophobic loading is used for encapsulation of 
certain drugs and leads to their increased stability and therapeutic effect [92, 93].
Due to the negative charge on the recipient cells, binding and uptake of EVs 
were enhanced by increasing the charge interactions with an artificially introduced 
positive surface potential, as exemplified in their derivatization with cationic 
lipids [94]. A downside of this method can be that the extremely charged cationic 
reagents can cause cytotoxicity and the cellular uptake of the modified particles 
can proceed differently from the usual pathways, which results in an unpredictable 
cellular fate of the particle and its cargo and possibly its undesired degradation. 
The innate slightly negative electrostatic potential exhibited by unmodified EVs 
should contribute to the longer half-life of such particles in vivo as inferred from 
liposomal studies [95]. Further, the extremes of unbalanced positive charge may 
negatively impact the storage stability and the application of such reagents in high 
concentrations.
As an alternative to other methods, labeling of EV surfaces with fluorescent 
probes has been achieved using click chemistry without an apparent effect on 
the size and function of the particles [96]. Nevertheless, there is an immense 
complexity behind the engineering and downstream methods developed for other 
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biologicals conjugated with small molecules, especially when intended for thera-
peutic purposes [97, 98].
The idea of decoration of EV membranes with functional ligands further led to 
the consideration of receptor binding strategies. Such EV functionalization can read-
ily be achieved by modification of the source cell. A resulting opportunity harvesting 
the specificity of this approach could also be used as a strategy to eliminate vesicles 
implicated in pathological processes, such as cancer metastasis, or to neutralize the 
undesired activity of therapeutically applied vesicles. Transferrin-conjugated super-
paramagnetic nanoparticles, reactive with surface-expressed transferrin receptor of 
exosomes, enabled their isolation from blood and endowed the vesicles with superior 
targeting properties [99]. A robust labeling approach of microvesicles was the 
expression of biotin acceptor peptide-transmembrane domain (BAP-TM) receptor 
on the source cells in combination with biotinylation in vivo [100].
Another example of employing an EV-localizing protein for efficient pre-
sentation on the EV surface involved a peptide or a protein fused with the C1C2 
domain of lactadherin, which binds to EV outer membrane due to its affinity to 
phosphatidylserine, strongly enriched in exosome membranes. This method was 
used to generate antibodies against tumor biomarkers [101] and to increase the host 
immune response to tumor-associated antigens [102, 103].
Strong binding of lactadherin to the exosome membrane was also the basis of 
an efficient labeling protocol utilizing overexpression of a fusion protein composed 
of Gaussia luciferase and a truncated lactadherin in source melanoma cells. After 
harvest by ultracentrifugation, the labeled exosomes were successfully used for in 
vivo biodistribution studies [104].
5.2 Engineering of tetraspanin proteins for detection and monitoring of EVs
Regarding the tetraspanins not only as very abundant, but as prominent struc-
tural and stability elements of the exosomal membrane, it is sensible to engineer 
genetic fusions of these proteins enriched in EVs to ensure a high density of the 
expressed product and optimize the derivatization for the different purposes of 
engineering: cognate ligand binding, labeling for visualization or isolation, modify-
ing cargo uptake and transfer and stability (Figure 3). Most practically, transgene 
Figure 3. 
Main engineering goals utilizing the modification of tetraspanins.
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expression in the parent cell would be induced to deliver EVs enriched in the 
modified protein. The success of such set-up depends on the understanding of both 
molecular biology and protein architecture of the targeted species.
In one of the pioneering studies, certain sites on the tetraspanin CD63 have 
been chosen to allow the integration of fluorescent fusion proteins on the extra- 
and intravesicular side of the exosomal membrane [105]. CD63-GFP fusions have 
proven valuable reporters in the elucidation of the role of immune synapse in secre-
tion of exosomes from T-cells to APCs and their fusion with recipient cells [106], in 
determining differential uptake properties of different immune cell subsets for EVs 
originating from a cancer cell line [107] and in an in vivo study imaging the fate of 
EVs produced by breast cancer cell line in nude mice [108].
5.3  Engineering of EV surface proteins for enhanced cell-type specific targeting: 
introduction of target specificity, stability and improved cargo delivery
In the pioneering example of derivatization of a protein enriched in exosomal 
membrane to achieve specific targeting [109], the rabies virus glycoprotein (RVG)-
peptide fused with lysosome-associated membrane glycoprotein 2b (Lamp-2b) was 
used to target exosomes to the central nervous system in an in vivo mouse model. 
Immature dendritic cells-derived exosomes, enriched in an N-terminal fusion of an 
αv integrin-specific internalizing RGD-sequence containing peptide with this scaf-
fold, could internalize efficiently into target-positive breast cancer cells [110]. The 
display of such constructs could be efficiently enhanced by introducing a protective 
glycosylation motive, which improved the surface expression of exosome-bound 
N-terminally fused peptides by preventing their acid-mediated proteolysis during 
endosomal passage and indeed led to a more efficient specific cellular uptake of 
exosomes engineered in this way [111]. Specific targeting of IL3-receptor overex-
pressing chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) 
cells has been shown for exosomes armed with a fusion protein of IL3 and Lamp2b 
and loaded with Imatinib, a tyrosine kinase inhibitor, and led to a the reduction 
of tumor size in vivo [112]. Exosomes engineered in this way achieved a higher 
abundance at the tumor site and were hence able to inhibit xenograft growth more 
efficiently than the active ingredient alone or than loaded control exosomes.
Glycosylphosphatidylinositol (GPI)-mediated anchoring of the specific tar-
geting unit was demonstrated to be a stable alternative to Lamp2b fusions. EVs 
expressing GPI-anchored nanobodies, specific to epidermal growth factor receptor 
(EGFR), displayed enhanced binding to the EGFR-overexpressing cancer cells. 
This, however, did not lead to an increased uptake, and it was suggested that in 
this particular biological system not only the affinity but also the density of the 
targeting ligand must be high enough to induce receptor clustering and subsequent 
internalization [113]. Exosomes derived from a HEK cell line transfected with 
a construct of platelet-derived growth factor (PDGF)-anchoring sequence and 
an EGFR-binding peptide were on the other hand efficient in targeting EGFR-
expressing tumors in vivo and reducing their size with delivery of microRNA Let7 
[114]. Enhanced uptake has been achieved for EVs enriched in a fusion protein of 
tetraspanin CD63 and stearylated octaarginine, a representative cell-penetrating 
peptide, by their ability to induce active macropinocytosis [115].
The concept of enhancing the stability of the targeted exosomal surface protein 
intended for fusion with a targeting agent to allow a higher degree of versatility for 
their modification for an improved target recognition has raised interest in their 
engineering at the protein level. A significant increase in thermal stability has been 
achieved by introduction of additional disulfide bonds in the EC2 of tetraspanin 
CD81, with the best variant exhibiting a positive shift in the melting temperature 
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for 45°C comparing with the wild-type protein [116]. When engrafted with a 
human transferrin-receptor specific peptide, the stabilized scaffold exhibited 
significantly better biophysical properties than the analogously engrafted wild-type 
protein. In the same study, a mutant has been discovered that exhibits reversible 
unfolding behavior up to a temperature of 110°C in contrast to the wild-type CD81 
EC2, which presents another option for extensive engineering required for directed 
evolution of tetraspanin proteins towards novel antigen binding.
Not only can the overexpression of tetraspanins in source cell lines increase the 
production and stability of exosomes, but also the exosomes engineered to con-
tain adeno-associated viruses (AAVs), designed for improved delivery of genetic 
material to target cell [100], were superior in their yield and functionality when 
CD9 was overexpressed in AAV-producer cells [10]. CD9 overexpression has also 
increased the speed and transduction efficiency of lentiviral gene delivery into 
numerous cell lines, confirming the important role of this tetraspanin in gene 
transfer [117].
The current scope of EV engineering reaches beyond receptor targeting systems 
and aspires towards modifications with complex modules, assigning them simulta-
neously with multiple novel functionalities, such as specific recognition as well as 
enzymatic activity, to enhance their potential therapeutic effect. Recently, regres-
sion of orthotopic Her2-positive tumors has been achieved by applying exosomes, 
able of specific targeting via their surface decoration with a fusion protein of 
high-affinity anti-Her2 single-chain Fv, and containing mRNA encoding a bacterial 
enzyme Hchr6, which in the strongly Her2-positive cells catalyzed the conversion 
of the prodrug CNOB to cytotoxic MCHB [118]. Tetraspanin engineering could 
support a sophisticated concept to aid intracellular delivery of exosomal cargo 
proteins, directionally incorporated during vesicle biogenesis [119]. Genes encoding 
two recombinant proteins, a fusion of photoreceptor cryptochrome 2 (CRY2) and 
the protein of interest and a fusion of tetraspanin protein CD9 and CRY-interacting 
basic-helix–loop–helix 1 (CIB1), were co-transfected into a single cell line. The blue 
light-induced binding of CRY2 and CIB1 enabled docking of CRY2-fused target 
proteins into nascent exosomes, and in the absence of the blue light, the cargo pro-
tein was released into the exosomal lumen. Transfer of Cre recombinase confirmed 
the efficiency of this system in vitro and in vivo.
6. Conclusions
The tetraspanins, well established as the biomarker proteins of extracellular 
vesicles, have been addressed for increasing EV stability and improving their 
function as delivery vehicles, both by assigning them with target recognition 
properties and modulating their cargo transfer. From the current point of view, 
the complexity of the tetraspanin-mediated interactions and signaling networks 
formed in a cell is yet to be discerned. Tetraspanins are known to interact naturally 
with a plethora of cell surface-bound ligands, which results in potent biological 
effects conveyed through different pathways; however, systematic evaluation of the 
affinity of the association with the interaction partners would assist in prediction of 
the consequential cellular processes as well as in determining optimal choice of the 
tetraspanin targeted for modification. There are recent reports describing modi-
fied tetraspanins mediating both surface protein interactions and an intracellular 
fusion-mediated enzymatic activity, which underline the feasibility of engineering 
versatile functions into tetraspanin proteins as fusion partners. The structural 
details on tetraspanins modified in this way, as well as the read-out revealing their 
actual behavior in the foreseen role and the influence of such modifications on 
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